GFM
VERV

GF Fund Management’s Verve Therapeutics VERV Stock Holding History

GF Fund Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,167
Closed -$24.3K – 683
2025
Q2 		$24.3K Hold
2,167
– – ﹤0.01% 484
2025
Q1 		$9.9K Buy
2,167
+389
+22% +$2.61K ﹤0.01% 567
2024
Q4 		$10K Buy
+1,778
New +$10K ﹤0.01% 542

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

GF Fund Management's VERV Position: Q3 2025 in Review

GF Fund Management sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 2,167 shares — an estimated $24.3K sold.

GF Fund Management first reported a position in VERV in Q4 2024 and held it in 3 quarters. The position peaked at $24.3K in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • GF Fund Management reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • GF Fund Management sold 2,167 Verve Therapeutics shares in Q3 2025, an estimated $24.3K.
  • GF Fund Management first reported a position in Verve Therapeutics in Q4 2024 and held it in 3 quarters.
  • GF Fund Management's Verve Therapeutics position peaked at $24.3K in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on GF Fund Management's 13F filing for Q3 2025, filed 7 Nov 2025.